公开(公告)号：US20180346439A1

公开(公告)日：2018-12-06

申请号：US15781862

申请日：2016-12-23

Applicant: DOOSAN CORPORATION

Inventor： Tae Jin CHOI ,  Jae Hoon LEE ,  Young Bae KIM

IPC: C07D319/24 ,  H01L51/00 ,  H01L51/50 ,  C07D405/04 ,  C07D405/10 ,  C07D407/04 ,  C07D407/10 ,  C07D409/04 ,  C07D409/10 ,  C07D417/10 ,  C07D413/10

CPC classification number: C07D209/82 ,  C07D307/91 ,  C07D319/14 ,  C07D319/24 ,  C07D333/76 ,  C09K11/06 ,  H01L51/00 ,  H01L51/50

Abstract: The present disclosure relates to a novel compound, and an organic electroluminescent device including the same, and by using the compound according to the present disclosure in an organic material layer, preferably a light emitting layer or an auxiliary light emitting layer, of an organic electroluminescent device, light emission efficiency, a driving voltage, a lifetime and the like of the organic electroluminescent device may be enhanced.

公开(公告)号：US20180339993A1

公开(公告)日：2018-11-29

申请号：US16050514

申请日：2018-07-31

Applicant: RaQualia Pharma Inc.

Inventor： Yuji SHISHIDO ,  Masashi OHMI ,  Kazuo ANDO

IPC: C07D491/056 ,  A61K31/538 ,  C07D235/06 ,  A61K31/423 ,  A61K31/4355 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  C07D413/10 ,  C07D235/02 ,  A61K31/517 ,  A61K31/435 ,  A61K31/422 ,  A61K31/4178 ,  C07D491/048 ,  C07D263/52 ,  C07D487/04 ,  C07D471/04 ,  C07D417/14 ,  C07D417/10 ,  C07D417/06 ,  C07D413/06 ,  C07D409/14 ,  C07D409/10 ,  C07D403/14 ,  C07D403/10 ,  C07D403/06 ,  C07D401/12 ,  A61K31/437 ,  A61K31/427 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14 ,  C07D403/12 ,  A61K31/4184

Abstract: The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor,

公开(公告)号：US20180327358A1

公开(公告)日：2018-11-15

申请号：US15776933

申请日：2016-12-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nicholas R. Wurtz ,  Pravin Sudhakar Shirude

IPC: C07D211/76 ,  C07D401/12 ,  C07D401/10 ,  C07D417/12 ,  C07D413/10 ,  C07D405/10 ,  C07D405/12 ,  C07D401/04 ,  C07D409/10 ,  C07D413/12 ,  C07D401/14

Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

公开(公告)号：US20180323378A9

公开(公告)日：2018-11-08

申请号：US14879979

申请日：2015-10-09

Applicant: Power OLEDs Limited

Inventor： Poopathy Kathirgamanathan

IPC: H01L51/00 ,  C07D339/08 ,  C07D409/10 ,  H01L51/50

CPC classification number: H01L51/0061 ,  C07D279/24 ,  C07D279/26 ,  C07D339/08 ,  C07D409/10 ,  C07D409/12 ,  C07D409/14 ,  C07D417/10 ,  C07F7/0812 ,  C07F9/4028 ,  C07F9/5355 ,  C07F9/655372 ,  C07F15/002 ,  C07F15/0033 ,  C07F15/0086 ,  H01L51/0052 ,  H01L51/0059 ,  H01L51/0071 ,  H01L51/0072 ,  H01L51/0074 ,  H01L51/5012 ,  H01L51/5056 ,  H01L51/5072 ,  H01L51/5088 ,  H01L2251/301 ,  Y02E10/549

Abstract: Compounds exhibiting high hole mobility and/or high glass transition temperatures are provided which are of the formula [Ar1]m[Ar2]n wherein: m is an integer from 1-3 and n is an integer and may be 1 or 2; Ar1 represents a thianthrene residue having a linkage to Ar2 at one or two positions selected from ring positions 1-4 and 5-8 and optionally mono-, bi- or poly-substituted with C1-C4-alkyl-, C1-C4-alkoxy-, fluoro, phenyl or biphenyl which in the case of phenyl or biphenyl may be further substituted with C1-C4-alkyl-, C1-C4-alkoxy- or fluoro; Ar2 represents a residue derived from an arylamine in which the aryl rings are phenyl, naphthyl or anthracenyl optionally substituted with C1-C4-alkyl-, C1-C4-alkoxy- or fluoro, a polycyclic fused or chain aromatic ring system optionally containing nitrogen or sulphur and in a chain aromatic ring system optionally containing one or more chain oxygen or sulphur atoms, a triarylphosphine oxide or an arylsilane the rings of any of which are optionally substituted with C1-C4-alkyl-, C1-C4-alkoxy- or fluoro. Certain of the compounds may be used in electron transport layers and may be doped with p-type dopants. They may be incorporated into OLEDs, organic photovoltaic devices, imaging members and thin film transistors.In further embodiments there are provided OLEDs or other devices e.g. electrostatic latent image forming members in which improved efficiency is obtained by using as electron transport layers, electron injectors, hosts and emitters (dopants) ambipolar or electron-transmitting compounds in which thianthrene is bonded to aryl e.g. 1-anthracenyl-9-yl-thianthrene, 1-biphenyl-4-yl-thianthrene and 9,10-Bis(1-thianthrenyl) anthracene.

公开(公告)号：US10053542B2

公开(公告)日：2018-08-21

申请号：US14423496

申请日：2013-07-10

Applicant: Merck Patent GmbH

Inventor： William Mitchell ,  Changsheng Wang ,  Nicolas Blouin ,  Mansoor D'Lavari ,  Jingyao Song

IPC: H01L51/54 ,  C08G75/06 ,  H01B1/20 ,  C08L81/02 ,  C07D519/00 ,  C07D495/04 ,  H01L51/05 ,  H01L51/42 ,  C07D495/22 ,  C08G61/12 ,  H01L51/00 ,  C07D409/10 ,  C07D498/22 ,  C07D513/22 ,  C07D517/22

CPC classification number: C08G75/06 ,  C07D409/10 ,  C07D495/04 ,  C07D495/22 ,  C07D498/22 ,  C07D513/22 ,  C07D517/22 ,  C07D519/00 ,  C08G61/126 ,  C08G2261/124 ,  C08G2261/1336 ,  C08G2261/1412 ,  C08G2261/148 ,  C08G2261/18 ,  C08G2261/3243 ,  C08G2261/414 ,  C08G2261/51 ,  C08G2261/91 ,  C08G2261/92 ,  C08G2261/95 ,  C08L81/02 ,  H01B1/20 ,  H01L51/0036 ,  H01L51/0043 ,  H01L51/0512 ,  H01L51/0558 ,  H01L51/4253 ,  Y02E10/549 ,  Y02P70/521

Abstract: The invention relates to novel conjugated polymers containing one or more polycyclic repeating units, to methods for their preparation and educts or intermediates used therein, to polymer blends, mixtures and formulations containing them, to the use of the polymers, polymer blends, mixtures and formulations as organic semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising these polymers, polymer blends, mixtures or formulations.

公开(公告)号：US20180230138A1

公开(公告)日：2018-08-16

申请号：US15751163

申请日：2016-08-26

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Xiaojun WANG ,  Pingjian ZHOU ,  Chuanwen YANG ,  Changwei HUANG ,  Shaohui XIONG ,  Yingjun ZHANG ,  Jiancun ZHANG

IPC: C07D407/10 ,  C07D307/85 ,  C07D413/14 ,  C07D409/10 ,  C07D413/10 ,  C07D405/10 ,  C07D407/12 ,  C07D471/04 ,  C07D417/10 ,  C07D411/10 ,  C07D417/14 ,  C07D407/14 ,  A61K45/06 ,  A61K31/343 ,  A61K31/4245 ,  A61K31/38 ,  A61K31/422 ,  A61K31/4196 ,  A61K31/4192 ,  A61K31/5377 ,  A61K31/351 ,  A61K31/41 ,  A61K31/382 ,  A61K31/397 ,  A61K31/4178 ,  A61K31/423 ,  A61K31/36 ,  A61K31/437 ,  A61K31/381 ,  A61K31/357 ,  A61K31/427 ,  A61K31/39 ,  A61K31/541 ,  A61K31/443 ,  A61K31/4355 ,  C07D493/04

CPC classification number: C07D407/10 ,  A61K31/275 ,  A61K31/343 ,  A61K31/351 ,  A61K31/357 ,  A61K31/36 ,  A61K31/38 ,  A61K31/381 ,  A61K31/382 ,  A61K31/39 ,  A61K31/397 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/443 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07C209/42 ,  C07C215/48 ,  C07C233/54 ,  C07C255/29 ,  C07C255/46 ,  C07C277/02 ,  C07D307/85 ,  C07D405/10 ,  C07D407/12 ,  C07D407/14 ,  C07D409/10 ,  C07D411/10 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  C07D471/04 ,  C07D493/04

Abstract: The invention relates to capthepsin K inhibitors and uses thereof, specifically relates to a class of compounds having the formula (I) which are used for treating or preventing cathepsin dependent diseases or conditions, specifically, wherein the cathepsin is capthepsin K. The compounds and compositions thereof can be used as bone resorption inhibitors for the treatment of associated diseases.

公开(公告)号：US20180222872A1

公开(公告)日：2018-08-09

申请号：US15748437

申请日：2016-07-01

Applicant: Merck Patent GmbH

Inventor： Anja Jatsch ,  Amir Hossain Parham ,  Thomas Eberle ,  Tobias Grossmann ,  Jonas Valentin Kroeber

IPC: C07D251/24 ,  H01L51/50 ,  C07D403/10 ,  C07D401/10 ,  C07D409/10 ,  C07D405/10 ,  C09K11/06 ,  H01L51/00

CPC classification number: C07D251/24 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C09K11/06 ,  C09K2211/1011 ,  C09K2211/1062 ,  C09K2211/1066 ,  H01L51/0052 ,  H01L51/0067 ,  H01L51/0072 ,  H01L51/5016 ,  H01L51/5076 ,  H01L51/5096 ,  Y02E10/549

Abstract: Fluorene derivatives that are connected in one or more of the 1-, 1′-, 4-, or 4′-positions in any combination to a carbon atom of a diaryl substituted triazinyl or pyrimidinyl derivative. The fluorene derivatives are not spirobifluorene derivatives. The compounds are suitable for use in electronic devices, in particular organic electroluminescent devices, comprising these compounds. In some embodiments, the compounds are used as matrix materials for phosphorescent or fluorescent emitters as well as a hole-blocking or an electron-transport layer.

公开(公告)号：US10035779B2

公开(公告)日：2018-07-31

申请号：US15187075

申请日：2016-06-20

Applicant: GlaxoSmithKline, LLC

Inventor： Duke M. Fitch ,  Antony N. Shaw ,  Kenneth Wiggall

IPC: C07D239/60 ,  A61K31/515 ,  C07D239/54 ,  C07D239/62 ,  C07D401/04 ,  C07D405/04 ,  C07D405/10 ,  C07D409/04 ,  C07D409/10 ,  C07D413/06 ,  C07D413/10 ,  C07D417/10 ,  C07D239/22

CPC classification number: C07D239/60 ,  A61K31/515 ,  C07D239/22 ,  C07D239/54 ,  C07D239/62 ,  C07D401/04 ,  C07D405/04 ,  C07D405/10 ,  C07D409/04 ,  C07D409/10 ,  C07D413/06 ,  C07D413/10 ,  C07D417/10

Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

公开(公告)号：US10020451B2

公开(公告)日：2018-07-10

申请号：US15229934

申请日：2016-08-05

Applicant: Semiconductor Energy Laboratory Co., Ltd.

Inventor： Hideko Inoue ,  Miyako Morikubo ,  Naoaki Hashimoto ,  Hiromi Seo ,  Satoshi Seo ,  Miki Kanamoto ,  Tomoka Nakagawa

IPC: H01L51/50 ,  H01L51/00 ,  C07D409/10 ,  C09K11/02 ,  C09K11/06

CPC classification number: H01L51/0067 ,  C07D409/10 ,  C09K11/025 ,  C09K11/06 ,  C09K2211/1007 ,  C09K2211/1044 ,  C09K2211/185 ,  H01L51/0052 ,  H01L51/0058 ,  H01L51/0059 ,  H01L51/006 ,  H01L51/0061 ,  H01L51/0072 ,  H01L51/0074 ,  H01L51/0085 ,  H01L51/5004 ,  H01L51/5016 ,  H01L51/5024 ,  H01L51/5072

Abstract: A light-emitting element with high heat resistance and high emission efficiency is provided. A novel heterocyclic compound that can be used in such a light-emitting element is provided. One embodiment of the present invention is a light-emitting element which includes, between a pair of electrodes, a layer containing a first organic compound, a second organic compound, and a light-emitting substance; the first organic compound includes one pyrimidine ring and one ring with a hole-transport skeleton; the second organic compound is an aromatic amine; and the light-emitting substance converts triplet excitation energy into light. A combination of the first organic compound, which includes the one pyrimidine ring and the one ring with the hole-transport skeleton, and the second organic compound, which is the aromatic amine, forms an exciplex.

公开(公告)号：US10016397B2

公开(公告)日：2018-07-10

申请号：US14908165

申请日：2014-07-17

Applicant: Charité-Universitaetsmedizin Berlin

Inventor： Jochen Springer ,  Stefan Anker ,  Andrew JS Coats

IPC: A61K45/06 ,  A61K31/4178 ,  A61K31/417 ,  C07D409/10

CPC classification number: A61K31/4178 ,  A61K31/417 ,  A61K45/06 ,  C07D409/10 ,  A61K2300/00

Abstract: The present invention is directed to selective AT2 receptor agonist or a pharmaceutically acceptable salt thereof for use in treatment of cachexia, preferably for use in treatment of cancer cachexia.